Our development pipeline consists of five clinical therapeutic candidates:
BL1020, an orally available, first in class antipsychotic indicated for the treatment of schizophrenia (Phase II/III commenced);
BL1040, a medical device developed for the prevention of cardiac remodeling in Acute Myocardial Infarction patients (Phase I/II clinical trial completed, CE Mark Registration trial commenced);
BL5010, a novel formulation for non surgical removal of skin lesions (Phase I/II clinical trial completed);
BL1021, a new chemical entity for neuropathic pain ( Phase I) and BL7040, a novel, orally available synthetic oligonucleotide for the treatment of inflammatory bowel disease (phase II commencing).
Thirteen additional compounds are currently in the pipeline at various stages of pre-clinical development.